Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Li, Yixin ^a   Kurlander, Roger J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD28 ANTIBODY; CD3 ANTIBODY; CD45RA ANTIGEN; CD57 ANTIGEN; CD70 ANTIGEN; CELL ANTIBODY; CHEMOKINE RECEPTOR CCR7; UNCLASSIFIED DRUG; CYTOKINE; LEUKOCYTE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL EXPANSION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MATERIAL COATING; PHENOTYPE; BIOSYNTHESIS; COMPARATIVE STUDY; CYTOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE;

ANTIGENS, CD; CYTOKINES; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 77958137842     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-104     Document Type: Article

References (44)

1. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935. 10.1182/blood-2009-08-239186, 19880495.
2. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009, 21:233-240. 10.1016/j.coi.2009.03.002, 19304471.
3. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005, 115:1616-1626. 10.1172/JCI24480, 1137001, 15931392.
4. Casado JG, DelaRosa O, Pawelec G, Peralbo E, Duran E, Barahona F, Solana R, Tarazona R. Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART-1-specific CD8+ T cells. Int Immunol 2009, 21:53-62. 10.1093/intimm/dxn123, 19050104.
5. Schwartz RH. A cell-culture model for lymphocyte-T clonal anergy. Science 1990, 248:1349-1356. 10.1126/science.2113314, 2113314.
6. Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB, June CH. Effects of CD28 costimulation on long-term proliferation of CD4(+) T cells in the absence of exogenous feeder cells. Journal of Immunology 1997, 159:5921-5930.
7. Garlie NK, LeFever AV, Siebenlist RE, Levine BL, June CH, Lum LG. T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother 1999, 22:336-345. 10.1097/00002371-199907000-00007, 10404435.
8. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, Veloso E, Zheng ZH, Westphal S, Mair R, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature medicine 2005, 11:1230-1237. 10.1038/nm1310, 16227990.
9. Stadtmauer EA, Rapoport AP, Levine BL, Badros A, Porter DL, Luger SM, Mann D, Cross A, June CH. Co-stimulated autologous T-cell infusion after autologous stem cell transplantation (SCT) for myeloma accelerates lymphocyte recovery and augments response to pneumoccal vaccine: Results of a randomized trial. Journal of Clinical Oncology 2005, 23:568S-568S.
10. Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SI, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng ZH, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34(+)-selected hernatopoietic cell transplantation. Blood 2003, 102:2004-2013. 10.1182/blood-2003-01-0095, 12763934.
11. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006, 107:1325-1331. 10.1182/blood-2005-08-3373, 16269610.
12. Laux I, Khoshnan A, Tindell C, Bae D, Zhu XM, June CH, Effros RB, Nel A. Response differences between human CD4+ and CD8+ T-cells during CD28 costimulation: Implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. Clin Immunol 2000, 96:187-197. 10.1006/clim.2000.4902, 10964536.
13. Riddell SR, Greenberg PD. The Use of Anti-Cd3 and Anti-Cd28 Monoclonal-Antibodies to Clone and Expand Human Antigen-Specific T-Cells. Journal of Immunological Methods 1990, 128:189-201. 10.1016/0022-1759(90)90210-M, 1691237.
14. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. Journal of Immunotherapy 2003, 26:332-342. 10.1097/00002371-200307000-00005, 2305721, 12843795.
15. Klapper JA, Thomasian AA, Smith DM, Gorgas GC, Wunderlich JR, Smith FO, Hampson BS, Rosenberg SA, Dudley ME. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. Journal of Immunological Methods 2009, 345:90-99. 10.1016/j.jim.2009.04.009, 2700005, 19389403.
16. Clement LT, Tilden AB, Dunlap NE. Analysis of the Monocyte-Fc Receptors and Antibody-Mediated Cellular Interactions Required for the Induction of T-Cell Proliferation by Anti-T3 Antibodies. Journal of Immunology 1985, 135:165-171.
17. Fleischer J, Soeth E, Reiling N, GrageGriebenow E, Flad HD, Ernst M. Differential expression and function of CD8O (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology 1996, 89:592-598. 10.1046/j.1365-2567.1996.d01-785.x, 1456589, 9014827.
18. Ju SW, Ju SG, Wang FM, Gu ZJ, Qiu YH, Yu GH, Ma HB, Zhang XG. A functional anti-human 4-1BB ligand monoclonal antibody that enhances proliferation of monocytes by reverse signaling of 4-1BBL. Hybridoma and Hybridomics 2003, 22:333-338. 10.1089/153685903322538872, 14678652.
19. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004, 101(2):14639-14645. 10.1073/pnas.0405730101, 521998, 15381769.
20. Kurlander RJ, Tawab A, Fan Y, Carter CS, Read EJ. A functional comparison of mature human dendritic cells prepared in fluorinated ethylene-propylene bags or polystyrene flasks. Transfusion 2006, 46:1494-1504. 10.1111/j.1537-2995.2006.00940.x, 16965575.
21. Hawkins ED, Hommel M, Turner ML, Battye FL, Markham JF, Hodgkin PD. Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data. Nature Protocols 2007, 2:2057-2067. 10.1038/nprot.2007.297, 17853861.
22. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712. 10.1038/44385, 10537110.
23. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature medicine 2002, 8:379-385. 10.1038/nm0402-379, 11927944.
24. Hamann D, Kostense S, Wolthers KC, Otto SA, Baars PA, Miedema F, van Lier RA. Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division. Int Immunol 1999, 11:1027-1033. 10.1093/intimm/11.7.1027, 10383934.
25. Rufer N, Zippelius A, Batard P, Pittet MJ, Kurth I, Corthesy P, Cerottini JC, Leyvraz S, Roosnek E, Nabholz M, Romero P. Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 2003, 102:1779-1787. 10.1182/blood-2003-02-0420, 12750165.
26. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, Corthesy P, Devevre E, Speiser DE, Rufer N. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol 2007, 178:4112-4119.
27. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003, 193:70-81. 10.1034/j.1600-065X.2003.00051.x, 12752672.
28. Snow AL, Oliveira JB, Zheng L, Dale JK, Fleisher TA, Lenardo MJ. Critical role for BIM in T cell receptor restimulation-induced death. Biol Direct 2008, 3:34. 10.1186/1745-6150-3-34, 2529272, 18715501.
29. Zhu YW, Zhu GF, Luo LQ, Flies AS, Chen LP. CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 2007, 109:4882-4889. 10.1182/blood-2006-10-043463, 1885532, 17244673.
30. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003, 101:4260-4266. 10.1182/blood-2002-11-3577, 12576317.
31. Duarte RF, Chen FE, Lowdell MW, Potter MN, Lamana ML, Prentice HG, Madrigal JA. Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy. Gene Therapy 2002, 9:1359-1368. 10.1038/sj.gt.3301807, 12365001.
32. Mercier-Letondal P, Montcuquet N, Sauce D, Certoux JM, Jeanningros S, Ferrand C, Bonyhadi M, Tiberghien P, Robinet E. Alloreactivity of ex vivo-expanded T cells is ecorrelated with expansion and CD4/CD8 ratio. Cytotherapy 2008, 10:275-288. 10.1080/14653240801927032, 18418773.
33. Carrasco J, Godelaine D, Van Pel A, Boon T, van der Bruggen P. CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation. Blood 2006, 108:2897-2905. 10.1182/blood-2005-11-007237, 16857986.
34. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 2006, 176:7726-7735. 1532931, 16751420.
35. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annual review of immunology 2004, 22:745-763. 10.1146/annurev.immunol.22.012703.104702, 15032595.
36. Ochsenbein AF, Riddell SR, Brown M, Corey L, Baerlocher GM, Lansdorp PM, Greenberg PD. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med 2004, 200:1407-1417. 10.1084/jem.20040717, 2211945, 15583014.
37. Speiser DE, Migliaccio M, Pittet MJ, Valmori D, Lienard D, Lejeune F, Reichenbach P, Guillaume P, Luscher I, Cerottini JC, Romero P. Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. European Journal of Immunology 2001, 31:459-466. 10.1002/1521-4141(200102)31:2<459::AID-IMMU459>3.0.CO;2-Y, 11180110.
38. Valenzuela HF, Effros RB. Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol 2002, 105:117-125. 10.1006/clim.2002.5271, 12482386.
39. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999, 190:705-715. 10.1084/jem.190.5.705, 2195613, 10477554.
40. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GMA, Papagno L, Ogg GS, King A, Lechner F, Spina CA, et al. Memory CD8(+) T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002, 8:379-385. 10.1038/nm0402-379, 11927944.
41. van Lier RAW, ten Berge IJM, Gamadia LE. Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol 2003, 3:931-938. 10.1038/nri1254, 14647475.
42. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, Carroll RG, Riley JL, June CH. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Molecular Therapy 2007, 15:981-988. 10.1038/mt.sj.6300134, 17375070.
43. Dotti G, Savoldo B, Brenner M. Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: "Are We Nearly There Yet?''. Human Gene Therapy 2009, 20:1229-1239. 10.1089/hum.2009.142, 19702437.
44. Heemskerk MH, Griffioen M, Falkenburg JH. T-cell receptor gene transfer for treatment of leukemia. Cytotherapy 2008, 10:108-115. 10.1080/14653240701883087, 18368589.